Britain and America have hammered out a major trade agreement that will keep no levies on British medicine exports going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to raise funding on medicines through the NHS. This commitment secures that tariffs on these key products will stay at zero for a duration of three years.
This development follows previous warnings to hike tariffs on branded drug imports, with increases mentioned reaching 100%.
"This arrangement with the Britain strengthens the international landscape for new treatments and introduces long-overdue equity to transatlantic medicine commerce," an announcement said.
Commercial Significance
Pharmaceuticals constitute one of the UK's biggest export categories to the United States, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to last September, the UK shipped drugs totaling over eleven billion pounds to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This agreement safeguards jobs, increases capital expenditure and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be restricted at 15%. Last year, refunds exceeded 20%.
Broader Context
This agreement takes place against a ongoing dispute between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were heightened by assertions that American patients were paying a premium for the identical medicines than patients in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.
